Drug intelligence / Profile preview

ABBV-142

Development stage: Phase 2
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ABBV-142 is a monoclonal antibody that acts as an antagonist of lysophosphatidic acid receptor 1 (LPAR1). It is being developed by AbbVie for the treatment of idiopathic pulmonary fibrosis and potentially other fibrotic diseases. As an LPAR1 antagonist, ABBV-142 targets a pathway implicated in tissue fibrosis, aiming to reduce or prevent the progression of fibrotic processes. The drug is currently undergoing Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and immunogenicity in healthy volunteers via both subcutaneous and intravenous administration[2][3][4][5].

Other names: ABBV 142ABBV142ABBV-142

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on ABBV-142.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-142.

Explore the full profile